Development of a human herpesvirus 8-negative effusion-based lymphoma during treatment with dasatinib for chronic myeloid leukemia
Journal of Clinical and Experimental Hematopathology · 2023
DOI: 10.3960/jslrt.22041 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Clinical and Experimental Hematopathology, 2023. Verfasst von Takahiro Suyama und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Nippon Koukan Hospital, Kanagawa, Japan. Hauptthemen laut MEDLINE: Herpesvirus 8, Human, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Pleural Effusion, Lymphoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Nippon Koukan Hospital, Kanagawa, Japan.
- Department of Hematology, Eiju General Hospital, Tokyo, Japan.
- Department of Pathology, Nippon Koukan Hospital, Kanagawa, Japan.
Zitieren
APA
Suyama, T., Hagihara, M., Matsui, N., Irie, R., Osamura, Y., Sakai, T., Watanabe, S., Umemoto, S., & Miyao, N. (2023). Development of a human herpesvirus 8-negative effusion-based lymphoma during treatment with dasatinib for chronic myeloid leukemia. Journal of Clinical and Experimental Hematopathology. https://doi.org/10.3960/jslrt.22041
Vancouver
Suyama T, Hagihara M, Matsui N, Irie R, Osamura Y, Sakai T, et al. Development of a human herpesvirus 8-negative effusion-based lymphoma during treatment with dasatinib for chronic myeloid leukemia. Journal of Clinical and Experimental Hematopathology. 2023. doi:10.3960/jslrt.22041
BibTeX
@article{Suyama2023,
author = {Suyama, Takahiro and Hagihara, Masao and Matsui, Naruaki and Irie, Rie and Osamura, Yoshiyuki and Sakai, Tetsuo and Watanabe, Shouichi and Umemoto, Shintarou and Miyao, Naoki},
title = {Development of a human herpesvirus 8-negative effusion-based lymphoma during treatment with dasatinib for chronic myeloid leukemia},
journal = {Journal of Clinical and Experimental Hematopathology},
year = {2023},
doi = {10.3960/jslrt.22041}
}
EUVIMED